While the maintenance of a Buy rating suggests continued confidence in HOOKIPA Pharma's fundamentals, the reduction in price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.